Remove Engineer Remove Gene Remove In-Vitro Remove In-Vivo
article thumbnail

Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies

Pharmaceutical Technology

The company can use its mammalian cell engineering expertise and capabilities to screen CAR T-cells, to discover and optimise next-generation therapeutic candidates for its partners. All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models.

In-Vivo 264
article thumbnail

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

The Pharma Data

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. MUNICH, Germany, Jan.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Stem cells’ versatility in drug development  

Drug Discovery World

Select mature stem cell lines can then be used in small-scale in vitro assays, and proven biochemical and phenotypic screens supporting target validation and deconvolution studies. Through the use of human induced pluripotent stem cells (iPSCs) derived cells, we can improve translation and reduce risk of clinical failure.

article thumbnail

Immuno-Oncology Summit Europe 2023: Programme highlights 

Drug Discovery World

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London.

article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. Optimer binders are engineered to overcome these problems. To what do you attribute your success?

article thumbnail

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo 52
article thumbnail

How mice with humanised immune systems are advancing cell-based immunotherapy

Drug Discovery World

In vivo models, particularly HIS models, allow preliminary investigation of cell-based therapeutic strategies—often in combination with other therapeutic modalities—to overcome the limitations and challenges of T cell-based immuno-oncology treatments and identify effective options for clinical investigation. Jespersen et al.

In-Vivo 52